Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
Relatively little information is available about the effects of salmeterol/fluticasone
combination and fluticasone alone in COPD patients with a partial reversible pulmonary
obstruction. The purpose of this study is to compare the effects of salmeterol/fluticasone
combination with fluticasone alone delivered via Diskus/ACCUHALER inhaler in subjects with
COPD on lung function over a 1 year period.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Xhance